Permanent Capital Management LP Makes New Investment in AbbVie Inc. $ABBV

Permanent Capital Management LP purchased a new stake in AbbVie Inc. (NYSE:ABBV) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 3,109 shares of the company’s stock, valued at approximately $720,000.

Other hedge funds have also modified their holdings of the company. Marshall & Sullivan Inc. WA acquired a new position in AbbVie in the second quarter valued at about $25,000. Evolution Wealth Management Inc. purchased a new stake in shares of AbbVie in the 2nd quarter valued at approximately $26,000. Spurstone Advisory Services LLC acquired a new position in shares of AbbVie in the 2nd quarter worth approximately $28,000. Financial Gravity Companies Inc. acquired a new position in shares of AbbVie in the 2nd quarter worth approximately $36,000. Finally, Delos Wealth Advisors LLC purchased a new position in shares of AbbVie during the 2nd quarter worth approximately $39,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ABBV. Scotiabank began coverage on AbbVie in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 target price on the stock. Evercore ISI lifted their price objective on AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a research note on Monday, September 22nd. Wells Fargo & Company increased their target price on AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a research note on Friday, September 12th. Citigroup lowered their target price on AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a report on Monday, November 3rd. Finally, UBS Group boosted their price target on shares of AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Three analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $245.84.

AbbVie Trading Up 0.1%

ABBV opened at $230.07 on Monday. The business has a fifty day moving average price of $226.73 and a 200 day moving average price of $212.72. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The stock has a market capitalization of $406.63 billion, a price-to-earnings ratio of 174.30, a PEG ratio of 1.31 and a beta of 0.36.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter last year, the business posted $3.00 EPS. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Sell-side analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is presently 496.97%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.